2023 World Conference on Lung Cancer (Posters)-P1.23. Circulating Tumour DNA as a Predictive Biomarker for Tumour Response and Prolonged Clinical Benefit with Nivolumab in NSCLC

P1.23. Circulating Tumour DNA as a Predictive Biomarker for Tumour Response and Prolonged Clinical Benefit with Nivolumab in NSCLC - PDF(Abstract)

Back to course

Pdf Summary

This presentation discusses the use of circulating tumor DNA (ctDNA) as a predictive biomarker for tumor response and clinical benefit with the drug nivolumab in patients with non-small cell lung cancer (NSCLC). The study included 44 NSCLC patients who received nivolumab treatment and underwent PET-CT scans every 6 cycles to evaluate their responses. Blood samples were taken from the patients at baseline and after 4 cycles of therapy, and ctDNA was quantified using a qubit dsDNA HS assay and NGS. A cut-off change of 50% in ctDNA levels was considered for molecular response.<br /><br />The results showed that patients with a time to progression (TTP) of less than 4 months had higher ctDNA concentrations compared to those with a TTP of 4 months or longer. Detectable alterations in ctDNA were observed in 31 patients, and a molecular response of 50% was seen in patients with partial response, stable disease, and a small number of patients with progressive disease. However, the overall survival did not show any significant trends. Further analysis revealed that a baseline ctDNA concentration of 0.3ng/microliter was predictive of progression-free survival, and ctDNA levels at 4 weeks were predictive of progression in patients who initially showed increased tumor size but later progressed.<br /><br />The study concludes that ctDNA concentration can be indicative of response and impending progression in NSCLC patients treated with nivolumab. A 50% cut-off for molecular response and a baseline ctDNA level of 0.3ng/microliter showed a trend for better progression-free survival. The authors emphasize the importance of serial monitoring using liquid biopsy and NGS for early prediction of response compared to radiologic evaluation.<br /><br />In summary, this study demonstrates the potential use of ctDNA as a predictive biomarker for tumor response and clinical benefit in NSCLC patients treated with nivolumab. The findings highlight the need for regular monitoring to assess treatment response and progression in these patients.

Asset Subtitle

Ullas Batra

Meta Tag

Speaker Ullas Batra

Topic Pathology & Biomarkers: Liquid Based Biomarkers

Keywords

circulating tumor DNA

ctDNA

predictive biomarker

tumor response

clinical benefit

nivolumab

non-small cell lung cancer

NSCLC

PET-CT scans

molecular response